Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.
Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Workman P, Waterfield MD, Parker P. Hayakawa M, et al. Among authors: kaizawa h. Bioorg Med Chem Lett. 2007 May 1;17(9):2438-42. doi: 10.1016/j.bmcl.2007.02.032. Epub 2007 Feb 15. Bioorg Med Chem Lett. 2007. PMID: 17339109
Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
Hirayama F, Koshio H, Ishihara T, Watanuki S, Hachiya S, Kaizawa H, Kuramochi T, Katayama N, Kurihara H, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S. Hirayama F, et al. Among authors: kaizawa h. Bioorg Med Chem. 2002 Aug;10(8):2597-610. doi: 10.1016/s0968-0896(02)00106-2. Bioorg Med Chem. 2002. PMID: 12057649
Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.
Hirayama F, Koshio H, Katayama N, Ishihara T, Kaizawa H, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kurihara H, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S. Hirayama F, et al. Among authors: kaizawa h. Bioorg Med Chem. 2003 Feb 6;11(3):367-81. doi: 10.1016/s0968-0896(02)00462-5. Bioorg Med Chem. 2003. PMID: 12517432
Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
Koshio H, Hirayama F, Ishihara T, Kaizawa H, Shigenaga T, Taniuchi Y, Sato K, Moritani Y, Iwatsuki Y, Uemura T, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S. Koshio H, et al. Among authors: kaizawa h. Bioorg Med Chem. 2004 Oct 15;12(20):5415-26. doi: 10.1016/j.bmc.2004.07.046. Bioorg Med Chem. 2004. PMID: 15388168
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P. Raynaud FI, et al. Among authors: kaizawa h. Cancer Res. 2007 Jun 15;67(12):5840-50. doi: 10.1158/0008-5472.CAN-06-4615. Cancer Res. 2007. PMID: 17575152 Free article.
Republication: Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours.
Boller D, Doepfner KT, Laurentiis A, Guerreiro AS, Marinov M, Shalaby T, Depledge P, Robson A, Saghir N, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Fattet S, Delattre O, Schweri-Olac A, Höland K, Grotzer MA, Frei K, Spertini O, Waterfield MD, Arcaro A. Boller D, et al. Among authors: kaizawa h. Anticancer Res. 2022 Jun;42(6):3217-3230. doi: 10.21873/anticanres.15812. Anticancer Res. 2022. PMID: 35641277 Free article.
Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours.
Boller D, Doepfner KT, De Laurentiis A, Guerreiro AS, Marinov M, Shalaby T, Depledge P, Robson A, Saghir N, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Fattet S, Delattre O, Schweri-Olac A, Höland K, Grotzer MA, Frei K, Spertini O, Waterfield MD, Arcaro A. Boller D, et al. Among authors: kaizawa h. Anticancer Res. 2012 Aug;32(8):3015-27. Anticancer Res. 2012. PMID: 22843869 Retracted.
13 results